PP
MRNS

PDT Partners’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

PDT Partners’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-37,207
Closed -$148K – 743
2022
Q4 		$148K Buy
37,207
+22,968
+161% +$113K 0.02% 562
2022
Q3 		$95K Buy
14,239
+1,288
+10% +$7.93K 0.01% 786
2022
Q2 		$63K Buy
+12,951
New +$78.8K 0.01% 908
2015
Q4 		– Sell
-2,950
Closed -$98K – 1019
2015
Q3 		$98K Buy
+2,950
New +$166K ﹤0.01% 1216

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return

PDT Partners's MRNS Position: Q1 2023 in Review

PDT Partners sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2023, closing a stake of 37,207 shares — an estimated $148K sold.

PDT Partners first reported a position in MRNS in Q3 2015 and held it in 4 quarters. The position peaked at $148K in Q4 2022. 86 funds tracked by Wall St. Rank hold MRNS as of Q1 2023.

  • PDT Partners reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2023 after selling out during the quarter.
  • PDT Partners sold 37,207 Marinus Pharmaceuticals, Inc shares in Q1 2023, an estimated $148K.
  • PDT Partners first reported a position in Marinus Pharmaceuticals, Inc in Q3 2015 and held it in 4 quarters.
  • PDT Partners's Marinus Pharmaceuticals, Inc position peaked at $148K in Q4 2022.
  • 86 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2023.

Based on PDT Partners's 13F filing for Q1 2023, filed 15 May 2023.